000300349 001__ 300349
000300349 005__ 20250603142719.0
000300349 0247_ $$2doi$$a10.1158/1055-9965.EPI-24-1440
000300349 0247_ $$2pmid$$apmid:40214978
000300349 0247_ $$2ISSN$$a1055-9965
000300349 0247_ $$2ISSN$$a1538-7755
000300349 037__ $$aDKFZ-2025-00783
000300349 041__ $$aEnglish
000300349 082__ $$a610
000300349 1001_ $$00000-0002-2061-0530$$aVerdiesen, Renée M G$$b0
000300349 245__ $$aCausal effects of breast cancer risk factors across hormone receptor breast cancer subtypes: A two-sample Mendelian randomization study.
000300349 260__ $$aPhiladelphia, Pa.$$bAACR$$c2025
000300349 3367_ $$2DRIVER$$aarticle
000300349 3367_ $$2DataCite$$aOutput Types/Journal article
000300349 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748953598_28538
000300349 3367_ $$2BibTeX$$aARTICLE
000300349 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300349 3367_ $$00$$2EndNote$$aJournal Article
000300349 500__ $$a2025 Jun 3;34(6):933-943
000300349 520__ $$aIt is unclear if established breast cancer risk factors exert similar causal effects across hormone receptor breast cancer subtypes. We estimated and compared causal estimates of height, body mass index (BMI), type 2 diabetes, age at menarche, age at menopause, breast density, alcohol consumption, regular smoking, and physical activity across these subtypes.We used a two-sample Mendelian randomization approach and selected genetic instrumental variables from large-scale GWAS. Publicly available summary-level BCAC data (n = 247,173; 133,384 cases, 113,789 controls) for the following subtypes were included: luminal A-like (45,253 cases); luminal B/HER2-negative-like (6,350 cases); luminal B-like (6,427 cases); HER2-enriched-like (2,884 cases); triple negative (8,602 cases). We employed multiple MR methods to evaluate the strength of causal evidence for each risk factor-subtype association.Collectively, our analyses indicated that increased height and decreased BMI are probable causal risk factors for all five subtypes. For the other risk factors, the strength of evidence for causal effects differed across subtypes. Heterogeneity in the magnitude of causal effect estimates for age at menopause and breast density was explained by null findings for triple negative tumours. Regular smoking was the sole risk factor for which there was no evidence for a causal effect on any subtype.This study suggests that established breast cancer risk factors differ across hormone receptor subtypes.Our results are valuable for the development of primary prevention strategies, improvement of breast cancer risk stratification in the general population, and for the identification of novel breast cancer risk factors.
000300349 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300349 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300349 7001_ $$aShokouhi, Mehrnoosh$$b1
000300349 7001_ $$00000-0001-5365-8760$$aBurgess, Stephen$$b2
000300349 7001_ $$00000-0003-3888-8829$$aCanisius, Sander$$b3
000300349 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b4
000300349 7001_ $$00000-0002-4061-4133$$aBojesen, Stig E$$b5
000300349 7001_ $$00000-0002-2228-429X$$aSchmidt, Marjanka K$$b6
000300349 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-24-1440$$n6$$p933-943$$tCancer epidemiology, biomarkers & prevention$$v34$$x1055-9965$$y2025
000300349 909CO $$ooai:inrepo02.dkfz.de:300349$$pVDB
000300349 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000300349 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300349 9141_ $$y2025
000300349 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2022$$d2024-12-10
000300349 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-10
000300349 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000300349 980__ $$ajournal
000300349 980__ $$aVDB
000300349 980__ $$aI:(DE-He78)C020-20160331
000300349 980__ $$aUNRESTRICTED